近日，北京义翘神州科技股份有限公司(以下简称：义翘神州)获得Scientist.com平台颁发的"2025年度供 应商绩效认可奖"(2025 Supplier Performance Recognition Award)，旨在表彰义翘神州在推动全球药物发 现研究方面做出的杰出贡献和卓越表现。 义翘神州通过哺乳动物细胞、杆状病毒-昆虫细胞、大肠杆菌及无细胞表达(CFPS)四大系统，为您提供 从基因合成到蛋白表达、纯化的一站式服务，是您定制重组蛋白表达的理想合作伙伴。义翘神州构建的 杂交瘤、Beacon®、流式单B、噬菌体和兔多抗技术五大抗体发现平台，成功开发30000+抗体，与很多 国际制药企业建立了良好的合作关系。 义翘神州美国公司首席商务官Rob Burgess表示： "我们深感荣幸能够获得Scientist.com的认可与肯定。也为双方长期而富有成效的合作深感自豪。这一奖 项充分彰显了我们团队致力于为全球科学界提供可靠、及时、创新解决方案的坚定承诺。未来，我们将 继续致力于赋能科研人员，为生命科学研究的进步贡献更大力量。" Scientist.com是全球大型的智能化生命科学研发采购平台，整合6000多家 ...

Core Viewpoint - Yiqiao Shenzhou announced on September 4 that its subsidiaries in Taizhou and Suzhou are progressing steadily in their respective businesses, with Taizhou's reagent and service operations experiencing relatively rapid growth, while Suzhou's biological safety testing services face longer market expansion cycles due to certification and client example requirements [1] Group 1 - The Taizhou subsidiary is engaged in reagent and service business, which does not require certification and is growing relatively quickly [1] - The Suzhou subsidiary primarily provides biological safety testing services, which require certification and client examples, leading to a longer market expansion cycle [1] - Overall, both subsidiaries are progressing according to plan and have shown a stable growth trend [1]